Daniel George
About Daniel George
Daniel George, age 54, has served as Anebulo’s part‑time Chief Financial Officer since September 2023, dedicating approximately 25% of his business time to the Company . He manages an executive financial services practice (active since May 2016; managing since December 2022) and previously held senior finance roles at multiple healthcare and medical device companies; he holds B.S. degrees in Accounting and Finance from California State University, Long Beach . His current compensation is via an offer letter at $400 per hour, and Anebulo reported $147,268 paid to him in fiscal 2024; no equity awards or bonuses were disclosed for him in that period . The proxy does not disclose Daniel-specific TSR, revenue growth or EBITDA growth metrics; discretionary bonuses for other executives were based on qualitative assessments rather than formulaic performance metrics .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Lucira Health, Inc. | Chief Financial Officer & Treasurer (full-time) | Aug 2020–Nov 2022 | Public diagnostics company; Lucira filed for bankruptcy in Feb 2023 and was acquired by Pfizer via bankruptcy auction in Apr 2023 . |
| Lucira Health, Inc. | CFO & Treasurer (consulting through his practice) | Apr 2019–Aug 2020 | Provided executive finance services during pre-IPO/early stage period . |
| Avinger, Inc. | Vice President, Finance | Aug 2014–May 2016 | Public medical device (peripheral atherectomy) finance leadership . |
| ApniCure, Inc. | Consultant & Vice President, Finance | Jun 2012–Aug 2014 | Sleep apnea device company; executive finance role . |
| Avantis Medical Systems, Inc. | Consultant & Chief Financial Officer | Mar 2009–Jun 2012 | Colonoscopy visualization technology; CFO and consultant . |
| FoxHollow Technologies Inc. | Sr. Director of Finance | Not disclosed | Public medical device company; senior finance management . |
| PricewaterhouseCoopers LLP | Assurance and business advisory | Not disclosed | Accounting and management consulting experience . |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Executive Financial Services Practice | Managing principal | Dec 2022–present | Provides executive financial services to healthcare companies; time allocation includes ~25% to Anebulo . |
| Executive Financial Services Practice | Founder/consultant | May 2016–present | Established consulting practice specializing in executive financial services . |
Fixed Compensation
| Component | FY 2024 Terms | FY 2024 Amount ($) |
|---|---|---|
| Hourly rate | $400/hour per offer letter (part-time CFO) | — |
| Salary/fees paid | Aggregate compensation between Sep 28, 2023 and Jun 30, 2024 | 147,268 |
| Base salary | Not applicable (hourly structure) | — |
Performance Compensation
| Metric | Weighting | Target | Actual | Payout | Vesting |
|---|---|---|---|---|---|
| Bonus | — | — | — | No bonus disclosed for FY 2024 | — |
| Stock awards (RSUs/PSUs) | — | — | — | None disclosed for FY 2024 | — |
| Option awards | — | — | — | None disclosed for FY 2024; no outstanding options as of Jun 30, 2024 | — |
| Performance metrics tied to pay | — | — | — | Executive bonuses (others) were discretionary, not formula-based; Daniel had none | — |
Equity Ownership & Alignment
| Category | Amount | Notes |
|---|---|---|
| Beneficial ownership (shares) | None reported | Daniel George listed with “—” in beneficial ownership table as of record date, indicating no reported ownership . |
| Ownership % of outstanding | — | Not reported; table shows “—” for Daniel George . |
| Options (exercisable/unexercisable) | None | Listed with no outstanding options as of Jun 30, 2024 . |
| Pledged shares | Not disclosed | No pledging disclosed in proxy for Daniel George . |
| Ownership guidelines | Not disclosed | No Daniel-specific stock ownership guideline disclosure . |
| Insider trading policy | In place | Company maintains insider trading policy; Rule 10b5‑1 plans permitted; prohibits trading on MNPI . |
| Clawback policy | In place | Board-adopted clawback allows recovery of incentive-based comp upon accounting restatement . |
Employment Terms
| Term | Detail |
|---|---|
| Role and time commitment | Part-time CFO since Sep 2023; ~25% business time to Anebulo . |
| Offer letter | Entered Sep 26, 2023; compensation at $400/hour . |
| Employment status | At-will (Company states each named executive officer’s employment is at will) . |
| Severance | Not disclosed for Daniel George; severance terms disclosed for other NEOs only . |
| Change-in-control (CIC) acceleration | Not eligible for accelerated vesting of Other Stock-Based Awards upon a Change in Control . |
| Restrictive covenants | Not disclosed for Daniel George; other NEO agreements include confidentiality and non-solicitation . |
Compensation Structure Analysis
- Executive bonus design at Anebulo emphasizes discretionary, qualitative assessments rather than formulaic performance metrics; Daniel George did not receive a discretionary bonus for FY 2024 .
- Equity alignment for Daniel appears minimal in FY 2024 given no reported ownership and no outstanding options, reducing equity-derived selling pressure but also limiting pay-for-performance linkage .
- Company maintains a clawback policy covering incentive-based compensation and a standard insider trading policy, supporting governance controls over compensation outcomes .
Related Party, Governance, and Committee Context
- Compensation Committee comprised of independent directors; met five times in fiscal 2024; engaged Pearl Meyer for market and peer group input; administers incentive plans and clawback policy .
- Compensation Committee procedures emphasize independence and discretion to use external advisors; CEO excluded from deliberations regarding his own pay .
- Board independence and leadership structure disclosed; broader governance context may influence comp oversight, though not Daniel-specific .
Performance & Track Record
- Daniel’s tenure includes leading finance at Lucira Health before the company filed for bankruptcy in February 2023 and was acquired by Pfizer via bankruptcy auction in April 2023, indicating exposure to distressed operating environments in diagnostics; the proxy does not attribute causality but discloses the outcome .
Investment Implications
- Alignment: Daniel’s compensation is hourly with no FY 2024 equity awards or disclosed ownership, indicating low equity alignment and minimal insider sell pressure; however, it also limits performance-based upside participation .
- Retention risk: Part-time status and at-will employment with no disclosed severance/CIC benefits suggest flexible engagement but potential retention fragility if external practice demands increase .
- Governance safeguards: Clawback and insider trading policies provide guardrails; absence of CIC acceleration for Daniel reduces change-of-control windfall risk .
- Execution risk: Prior experience through Lucira’s bankruptcy underscores familiarity with restructuring and liquidity management under stress; investors should weigh that background neutrally as situational context rather than performance attribution .